Ga-DWJ155

Phase 1Small molecule

Novartis

Ga-DWJ155 is one of 26 small molecule programs targeting Breast Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast NeoplasmsRecruiting

Breast NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

27 competitors in Breast Neoplasms

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

7 2

Abraxane

Bristol-Myers Squibb

Phase 3

4 3

Keytruda

Merck & Co.

Phase 3

4 4

Verzenio

Eli Lilly

Phase 3

4 5

Aromasin

Pfizer

Phase 3

3 6

Ibrance

Pfizer

Phase 3

3 7

Perjeta

Roche

Phase 3

2 8

Trodelvy

Gilead

Phase 3

2 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

6 10

Faslodex

FFresenius Kabi USA, LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Breast Neoplasms

NCT07117214

Clinical

Trials by Indication[1]

Breast Neoplasms1 trial

A Phase I, Open Label First in Human Study to Evaluate the Imaging Performance, Safety, Biodistribution and Pharmacokinetics of [68Ga]Ga-DWJ155 in Adult Patients With Advanced Breast Cancer and Advanced NSCLC

Recruiting· Novartis logo

Novartis·Phase 1·NCT07117214·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ga-DWJ155. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga-DWJ155 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga-DWJ155. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novartis

Ga-DWJ155

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Breast Neoplasms1 trial

References

Drug Info

Quick Facts

Related News